{
    "clinical_study": {
        "@rank": "102424", 
        "arm_group": {
            "arm_group_label": "p-AKT", 
            "description": "p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)"
        }, 
        "biospec_descr": {
            "textblock": "paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway.\n      However, clinical information about the significance of p-AKT expression in malignant\n      lymphoma is not fully understood yet. In this study, we investigated the overexpression of\n      p-AKT and its prognostic implication in malignant lymphoma."
        }, 
        "brief_title": "p-AKT Expression on Clinical Outcomes in Malignant Lymphoma", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Malignant Lymphoma", 
            "P13K-AKT Pathway Deregulation"
        ], 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "Recently, among diverse oncogenic signaling pathways, a number of studies have focused on\n      the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine\n      kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol\n      3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and\n      plays a critical role promoting malignant phenotype and has prognostic significance in\n      various solid cancers.\n\n      However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes\n      has not been performed in malignant lymphoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. the patients were pathologically confirmed of malignant lymphoma, according to the\n             World Health Organization classification;\n\n          2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for\n             immunostaining of p-AKT.\n\n        Exclusion Criteria:\n\n        1. Primary central nervous system lymphoma was excluded in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "17 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with malignant lymphoma who are treated in a tertiary hospital in Korea (Samsung\n        Medical Center)"
            }
        }, 
        "enrollment": {
            "#text": "262", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789060", 
            "org_study_id": "2013-01-047"
        }, 
        "intervention": {
            "arm_group_label": "p-AKT", 
            "description": "p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides", 
            "intervention_name": "p-AKT immunohistochemical staining", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study", 
        "other_outcome": {
            "measure": "Subgroup analysis of overall survival according to International Prognostic Index risk groups", 
            "safety_issue": "No", 
            "time_frame": "study entry"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Won Seog Kim, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Difference of overall survival according to p-AKT status in malignant lymphoma", 
            "safety_issue": "No", 
            "time_frame": "study entry"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789060"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Won Seog Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)", 
            "safety_issue": "No", 
            "time_frame": "study entry"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}